Great Lakes Advisors LLC Lowers Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Great Lakes Advisors LLC lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 20.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 178,477 shares of the biopharmaceutical company's stock after selling 46,132 shares during the quarter. Great Lakes Advisors LLC owned approximately 0.06% of Amicus Therapeutics worth $1,681,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. KBC Group NV grew its stake in shares of Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 3,120 shares during the last quarter. Legacy Capital Group California Inc. grew its stake in shares of Amicus Therapeutics by 20.2% during the fourth quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 3,900 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Amicus Therapeutics during the third quarter worth $55,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Amicus Therapeutics by 11.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company's stock worth $597,000 after buying an additional 6,314 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its stake in shares of Amicus Therapeutics by 46.3% during the third quarter. Los Angeles Capital Management LLC now owns 20,474 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 6,484 shares during the last quarter.

Remove Ads

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on FOLD. Morgan Stanley reiterated an "equal weight" rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company cut their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, February 20th. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $16.75.

Amicus Therapeutics Trading Up 2.4 %

FOLD stock traded up $0.22 during midday trading on Wednesday, hitting $9.20. The stock had a trading volume of 1,865,165 shares, compared to its average volume of 2,400,947. The firm has a market cap of $2.83 billion, a P/E ratio of -51.11, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 1-year low of $8.55 and a 1-year high of $12.65. The business has a fifty day moving average price of $9.36 and a two-hundred day moving average price of $10.11.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.